Background-There is general agreement that the optimal duration of dual antiplatelet therapy (DAPT) in patients treated with drug-eluting stents should be individualized. We hypothesized that the extent of coronary artery disease may affect the clinical outcomes of DAPT. Methods and Results-We pooled patient-level data from 5 large, randomized trials comparing short-term DAPT with prolonged therapy. From the data, we identified 5476 patients who received newer-generation drug-eluting stents. Net adverse clinical event (NACE) was defined as a composite of all-cause mortality, myocardial infarction, stroke, or major bleeding. At 1 year, NACE had occurred in 171 patients (3.1%). Independent predictors of NACE were older age (>65 years), sex, presence of diabetes mellitus, left ventricular dysfunction (ejection fraction <40%), and angiographic multivessel disease. Multivessel disease and DAPT duration were significantly associated with NACE (P for interaction=0.002); the association was driven by the greater occurrence of myocardial infarction in patients with multivessel disease. In patients with multivessel disease, 6-month DAPT (versus 12-month DAPT) was associated with a higher incidence of myocardial infarction (adjusted hazard ratio=2.748; 95% confidence interval=1.375-5.491; P=0.004), compared with patients with single-vessel disease (P for interaction=0.001). Conclusions-In patients treated with newer-generation drug-eluting stents, a significant interaction between DAPT strategy and multivessel disease was found regarding the occurrence of NACE at 1 year. Among adverse events, myocardial infarction was more frequent in 6-month DAPT than in 12-month DAPT in patients with multivessel disease. (Circ Cardiovasc Interv. 2016;9:e004256.
C ompared with first-generation drug-eluting stents (DES), contemporary DES has been shown to improve clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) and is the standard of care in current practice. In a meta-analysis of 11 randomized trials with 16 775 patients, everolimus-eluting stents were associated with a significant reduction in stent thrombosis compared with first-generation DES. 1 Other newer-generation DES, including zotarolimuseluting stents and biolimus-eluting stents, have shown efficacy and safety similar to everolimus-eluting stents 2 and fewer very late stent thrombosis events compared with first-generation sirolimus-eluting stents. 3 The enhanced properties of newergeneration DES compared with older-generation DES have been confirmed in real-world studies. 4 A lower risk of definite stent thrombosis was found with newer-generation DES in a large registry of 94 384 consecutive stent implantations. DAPT and Multivessel Disease in DES-treated patients without a high bleeding risk. 5 This recommendation has been challenged by several studies in which early discontinuation of dual antiplatelet therapy (DAPT) was not associated with an excess of major adverse cardiac events (MACE) compared with the recommended duration of DAPT. [6] [7] [8] [9] [10] However, the largest randomized trial, which compared 12 and 30 months of DAPT in ≈10 000 DES patients showed a significant reduction in MACE with the longer duration of DAPT. 11 The 2016 ACC/AHA guideline-focused update on the duration of DAPT in patients with coronary artery disease was recently released. 12 On the basis of the systematic review about the duration of DAPT, 13 the minimum recommended duration of DAPT has been decreased from 12 to 6 months in patients with stable ischemic heart disease. This change was based on the findings from previous randomized trials that compared shorter-duration DAPT with 12 months of DAPT primarily in low-risk DES-treated patients. 6, 7, 9 However, data about an individualized approach to short duration of DAPT after DES implantation are still limited.
In the present study, we hypothesized that the association between the DAPT strategy (short-term versus prolonged therapy) and clinical outcomes would be influenced by patients' underlying disease. We investigated the clinical outcomes in patients treated with contemporary newer-generation DES from a patient-level pooled database of randomized trials of DAPT durations.
Methods

Study Design and Population
Eligible studies for the present analysis were randomized controlled trials that compared short-term DAPT (3 or 6 months) with prolonged DAPT (≥1 year) in patients undergoing DES implantation. Randomized trials comparing 1 year with >1 year DAPT or using older-generation DES in all allocated patients were excluded. The study rationale and search strategy have been previously reported.
14 Briefly, relevant randomized trials were searched through MEDLINE, the Cochrane database, the EMBASE database, https://www.clinicaltrials.gov, https:// www.clinicaltrialresults.org, https://www.cardiosource.org, abstracts and presentations from major cardiovascular meetings, and http://www. tctmd.com using the keywords "randomized clinical trial," "drug-eluting stent," "dual antiplatelet therapy," "clopidogrel," "aspirin," and "thienopyridines." Authorized investigators independently reviewed the titles, abstracts, and studies to determine whether they met the inclusion criteria. Reviewer conflicts were resolved by consensus. Internal validity of randomized controlled trials was evaluated considering concealment of allocation, blind adjudication of events, and inclusion of all randomized patients in the analysis. Individual participant data were obtained from the principal investigators of all qualifying trials and merged in a single pooled database. In addition to previously included 3 randomized trials, [6] [7] [8] the present study included the SECURITY trial (Second Generation Drug-Eluting Stent Implantation Followed by 6-Versus 12-Month Dual Antiplatelet Therapy) and ITALIC trial (Is There a Life for DES After Discontinuation of Clopidogrel). 9, 10 Among 8354 patients from the merged individual participant database, we identified patients who received newer-generation DES: Endeavor Resolute (Medtronic, Minneapolis, MN), Xience (Abbott Vascular, Abbott Park, IL), Promus (Boston Scientific, Natick, MA), Nobori (Terumo Corporation, Tokyo, Japan), or Biomatrix (Biosensors Europe, Morges, Switzerland). Selected patients were as follows: 718 patients implanted with Resolute zotarolimus-or everolimus-eluting stents from the RESET trial (A New Strategy Regarding Discontinuation of Dual Antiplatelet); 1038 patients implanted with everolimus-eluting stents from the EXCELLENT trial (Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting); 500 patients implanted with everolimus-eluting stents from the PRODIGY trial (Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention); 1326 patients implanted with a Resolute zotarolimus-, everolimus-, or biolimus-eluting stent from the SECURITY trial; and 1894 patients implanted with everolimus-eluting stents from the ITALIC trial. Accordingly, 5476 patients were included in the present analysis. The study protocols of these trials were approved by the Institutional Review Board of each participating institution, and written consent was obtained from all patients.
PCI and DAPT
DES implantation was performed according to standard techniques. The interventional strategy, including use of glycoprotein IIb/IIIa inhibitors, predilation, or postdilation, was left to the interventionist's discretion. The selection of DES followed the specific study protocol. After PCI, aspirin (80-160 mg, daily) was prescribed indefinitely. The administration of clopidogrel 75 mg/d (or prasugrel 60 mg/d, or ticagrelor 90 mg BID) depended on the randomized assignments in each trial. [6] [7] [8] [9] [10] Specifically, patients with newer-generation DES were only allocated to prolonged DAPT in the RESET trial. 
End Points and Definitions
The primary end point was the 1-year rate of net adverse clinical event (NACE) that was defined as a composite of all-cause death, myocardial infarction, stroke, or major bleeding. The secondary end point was the 1-year rate of MACE that was defined as a composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis. Definitions of end points as applied in each trial were summarized in Table I in the Data Supplement and were incorporated in the present study. In 4 trials, bleeding was defined according to the TIMI criteria (Thrombolysis in Myocardial Infarction), [6] [7] [8] 10, 15 and the BARC (Bleeding Academic Research Consortium) was used in 1 trial. 9, 16 Major bleeding was defined as the occurrence of major type of TIMI bleeding and type 3 or 5 BARC bleeding. 15, 16 Clinical outcomes beyond 1 year were not assessed because most data were censored.
Statistical Analysis
Statistical analysis was performed using SPSS (version 18.0.0; SPSS, Inc, Chicago, IL) and R (version 2.8.0; R Foundation for Statistical
WHAT IS KNOWN
• Dual antiplatelet therapy is recommended for at least 6 months after drug-eluting stent implantation in stable ischemic heart disease.
• Prolonged use of DAPT increases the risk of bleeding and sometimes complicates other medical situations such as oral anticoagulant use and unexpected noncardiac surgery.
• The data about an individualized approach to short duration of DAPT after newer-generation drug-eluting stent implantation are still limited.
WHAT THE STUDY ADDS
• In patients treated with newer-generation drug-eluting stents, 6-month DAPT was associated with an increased risk of myocardial infarction compared with 12-month DAPT in patients with multivessel disease.
• Prolonged DAPT may be useful in patients with multivessel disease treated with contemporary drug-eluting stents who do not have an excessive bleeding risk.
DAPT and Multivessel Disease
Computing, Vienna, Austria). Categorical variables were reported as numbers and percentages and were compared using the χ 2 test. Continuous variables were reported as mean±SD and were analyzed using Student t test. The analysis of individual patient data was performed using a 1-stage approach. To identify independent predictors for NACE, a multivariable logistic regression model that involved a generalized linear mixed model to account for each trial as a random effect was used. Variables with a P value of <0.10 on univariable analysis were tested in the multivariable model: older age (>65 years), sex, diabetes mellitus, left ventricular dysfunction (ejection fraction <40%), and multivessel disease. From the pooled patient-level database, we examined the relative risk of NACE in the post hoc subgroups that were also NACE predictors: age, sex, diabetes mellitus, left ventricular dysfunction, and multivessel disease. Clinical events at 1 year (360 days) after randomization were analyzed using the multivariable Cox regression model stratified by trial. The following variables were tested in the multivariable model: older age, sex, diabetes mellitus, left ventricular dysfunction, and type of DES. The intention-to-treat population was used for these analyses, including all patients according to randomized treatment arm regardless of actual treatment.
14 Landmark analyses were performed at time of DAPT discontinuation using an as-treated cohort. 14 For this analysis, patients with clinical events occurring before the landmark time point, those with premature discontinuation of DAPT, and those in whom DAPT was prolonged ≥1 month beyond the period scheduled by randomization were excluded.
14 For descriptive purposes, a simple Cox regression model was used to generate cumulative hazard function curves of adverse events for clinical outcomes.
14 Publication bias of selected trials was assessed by visual inspection of funnel plot, showing neither small study effects nor publication bias ( Figure I in the Data Supplement). All P values were 2 sided, and a P value <0.05 was considered statistically significant. Using Bonferroni adjustment, a significant P value was defined <0.01 in multiple subgroup analyses.
Results
Predictors of NACE
The study flow and characteristics of included randomized trials are shown in Figure II and Table II in the Data Supplement. Of the initially screened 1042 articles, 5 trials were included in the present study. At 1 year after newer-generation DES implantation, NACE occurred in 171 patients (3.1%): 64 all-cause deaths, 70 cases of myocardial infarction, 23 cases of stroke, and 28 cases of major bleeding. MACE occurred in 102 patients (1.9%): 30 cardiac deaths, 70 cases of myocardial infarction, and 13 cases of definite/probable stent thrombosis. Table 1 lists clinical and procedural characteristics according to the presence of NACE. Patients with NACE were older and more often women compared with patients who had not experienced NACE. In addition, comorbidities including diabetes mellitus and left ventricular dysfunction were more frequently observed in patients with NACE. Multivessel disease was more common in patients with NACE; consequently, the number of treated vessels was greater in those with NACE. However, clinical presentation, types of DES used, or DAPT duration were not different between patients with NACE and those without NACE. By multivariable regression analysis, independent predictors for NACE were older age (>65 years), female sex, diabetes mellitus, left ventricular dysfunction, and multivessel disease ( Table 2) . Figure 1 shows the association between NACE predictors and DAPT duration. A significant interaction was present between the presence of multivessel disease and DAPT duration for the NACE end point (P for interaction=0.002), as also shown in Figure III in the Data Supplement stratified by trial. With the exception of multivessel disease, none of the other predictors showed a significant association between the DAPT strategy and NACE. Table 3 shows details of ischemic and bleeding events in patients with single-and multivessel disease. In patients with single-vessel disease, there was no difference in clinical events between 6-and 12-month DAPT. However, in patients with multivessel disease, MACE occurred more frequently in patients who had received 6-month DAPT (adjusted hazard ratio=2.443; 95% confidence interval=1.339-4.459; P=0.004; P for interaction=0.001), which was mainly driven by an increased incidence of myocardial infarction (adjusted hazard ratio=2.748; 95% confidence interval=1.375-5.491; P=0.004; P for interaction=0.001). Myocardial infarction that was not related to stent thrombosis accounted for 85.7% (36/42) of these events among patients with multivessel disease. Differences also were observed between DAPT discontinuation and 12 months (Figure 2) . Figure 3 shows the occurrence of myocardial infarction between DAPT discontinuation and 12 months in the subgroup of patients with multivessel disease, according to the clinical presentation. Compared with 12-month DAPT, a tendency toward increased myocardial infarction in patients who received 6-month DAPT was observed in patients with acute coronary syndrome.
Multivessel Disease and DAPT
Discussion
In this pooled analysis, the incidence of NACE was ≈3% at 1 year after newer-generation DES implantation. NACE predictors were older age, female sex, diabetes mellitus, left Figure 1 . Associations between predictors of net adverse clinical event (NACE) and dual antiplatelet therapy (DAPT). Unadjusted hazard ratio (HR) with 95% confidence interval (CI) was for 6-mo DAPT relative to 12-mo DAPT. DAPT and Multivessel Disease ventricular dysfunction, and angiographic multivessel disease at index procedure. Among these predictors, shorter-duration (6 month) DAPT was associated with an increased risk of myocardial infarction and MACE compared with 12-month DAPT in patients with multivessel disease, which favored the longer-term maintenance of DAPT in this subset of patients. Given the inherent difficulties in weighing ischemic and bleeding risks in individual patients, determining the optimal duration of DAPT after DES implantation can be challenging. In the present study, NACE was chosen as the primary study end point to evaluate net clinical effects of included patients because both severe cardiocerebral ischemic and bleeding events after successful PCI caused the mortality. According to previous studies, factors related to ischemic events were slightly different from those associated with bleeding events although several factors such as older age or renal insufficiency contributed to the occurrence of both events. [17] [18] [19] [20] [21] [22] [23] Risk factors for ischemic events included diabetes mellitus, acute coronary syndrome, congestive heart failure, and multivessel coronary artery disease, whereas bleeding-related factors contained female sex and baseline anemia. [17] [18] [19] [20] [21] [22] [23] Putting these findings together, the present NACE predictors may reflect both sides of adverse clinical events. Unexpectedly, the clinical presentation of acute coronary syndrome was not associated with NACE. However, this finding was also observed in previous studies that evaluated MACE predictors in patients receiving newer-generation DES, namely, everolimus-eluting stent. 24, 25 Although the improved efficacy of newer-generation DES compared with previous coronary stents may be correlated, it is necessary to be validated by other studies.
Recently, risk-scoring system derived from the DAPT study has been introduced to guide whether thienopyridine treatment will continue or not after 12 months of DAPT. 26 Factors associated with the benefit/risk ratio for prolonged DAPT were younger age, current smoking status, diabetes mellitus, clinical presentation of acute myocardial infarction, history of myocardial infarction, congestive heart failure, usage of paclitaxeleluting stent, stent diameter <3 mm, and vein graft stenting. 26 However, findings derived from the DAPT trial can be applied to patients 12 months after DES implantation, and data about early discontinuation of DAPT are still insufficient. Notably, the extent of coronary artery disease was tested neither in the DAPT study nor in the subsequent prediction model. 11, 26 This variable was also not considered as candidate predictor for risk model building in PARIS registry (Patterns of Non-Adherence to Dual Anti-Platelet Regimen in Stented Patients). 27 Results from the present study suggested that the early discontinuation of P2Y 12 inhibitors even after newer-generation DES implantation may be associated with a risk of developing subsequent myocardial infarction (mainly nonstent thrombosis related) in patients with multivessel disease. This phenomenon was prominent in patients who presented with acute coronary syndrome but not in those who presented with stable coronary artery disease. Although previous randomized trials comparing shortterm with 12-month DAPT have not demonstrated significant associations between prespecified subgroups and DAPT strategy, the sample size of each of these trials was underpowered for subgroup analysis. [6] [7] [8] In addition, a recent meta-analysis showed no apparent association between DAPT assignment and clinical characteristics.
14 However, this study included first-generation sirolimus-eluting stent (8.2% of included patients) and paclitaxel-eluting stent (6.3% of included patients), and DES types were significantly different between short-term and long-term DAPT groups.
14 Given that adverse cardiac events related to stent thrombosis have been more common in patients treated with first-generation DES than in those receiving newer-generation DES, [1] [2] [3] [4] any possible interaction between DES type and DAPT duration cannot be excluded in the meta-analysis from Palmerini et al. 14 However, newergeneration DES-treated patients were exclusively included and analyzed in the present study. Actually, an observed MACE rate of short-term DAPT group was numerically lower in the present study (2%) compared with the previous meta-analysis (3%).
14 Conversely, the current finding that short-term DAPT may be associated with a greater occurrence of myocardial infarction in patients with multivessel disease treated with contemporary DES is consistent with some previous studies. In a post hoc analysis of the CHARISMA trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance), which evaluated the clinical outcomes of clopidogrel plus aspirin therapy (versus placebo plus aspirin) in patients with documented coronary artery disease, cerebrovascular disease, or peripheral artery disease, or with multiple risk factors for atherothrombosis, patients with established coronary artery disease seemed to derive significant benefit from DAPT. 28 Also, in the DAPT trial, both stentrelated and non-stent-related myocardial infarctions were increased after the discontinuation of thienopyridine.
11 From the CASCADE randomized trial (Clopidogrel After Surgery for Coronary Artery Disease), which investigated the effects of DAPT on the progression of native coronary artery disease after coronary artery bypass grafting, the change of stenotic 29 The present analysis extended the findings from these earlier studies by indicating that extending DAPT to at least 1 year may reduce MACE in patients with multivessel disease treated with contemporary DES.
Limitations
Several limitations of the current study should be considered. First, the individual patient data from the ISAR-SAFE trial (Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting) were not obtained. 30 The lack of inclusion of ISAR-SAFE trial in the present analyses (number of possible participants=2717) may potentially introduce a possibility of bias. Second, the present findings should be interpreted considering limitations of each trial such as lack of doubleblind design and randomization at index procedure rather than at time of treatment divergence because the knowledge of treatment assignment could influence on results. Third, our results should be considered hypothesis generating because they were not prespecified. Fourth, we could not determine whether novel antiplatelet agents including prasugrel and ticagrelor would provide different results. Fifth, DAPT and PARIS score were not tested in this study because information of each variable in DAPT and PARIS score was not sufficient in the current data set. Sixth, the comprehensive risk prediction model for patients within 1 year after DES implantation may be necessary to guide the early discontinuation of DAPT. Finally, because additional meta-analyses using 2-stage approach or Bayesian framework was not performed, the present results may be less robust.
Conclusions
In a pooled analysis of 5476 patients treated with widely used newer-generation DES, a significant interaction between DAPT strategy and multivessel disease was found on the occurrence of NACE at 1 year. Among adverse events, myocardial infarction was more frequent in 6-month DAPT compared with 12-month DAPT in the subset of patients with multivessel disease. 
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